Matt Hewitt
Stock Analyst at Craig-Hallum
(2.70)
# 1,906
Out of 5,182 analysts
44
Total ratings
55.26%
Success rate
3.5%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MXCT MaxCyte | Maintains: Buy | $7 → $5 | $0.88 | +470.06% | 2 | Mar 25, 2026 | |
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $14.87 | +142.10% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $5.90 | +103.39% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.64 | +127.27% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $20.90 | +53.11% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $45.51 | +40.63% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $232.32 | -39.74% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.29 | +3,371.02% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $12.24 | +145.10% | 3 | May 2, 2024 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $117.43 | +70.31% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.40 | +614.29% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $6.00 | +400.00% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $4.56 | +8,671.93% | 1 | Jan 4, 2022 |
MaxCyte
Mar 25, 2026
Maintains: Buy
Price Target: $7 → $5
Current: $0.88
Upside: +470.06%
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $14.87
Upside: +142.10%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $5.90
Upside: +103.39%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.64
Upside: +127.27%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $20.90
Upside: +53.11%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $45.51
Upside: +40.63%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $232.32
Upside: -39.74%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.29
Upside: +3,371.02%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $12.24
Upside: +145.10%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $117.43
Upside: +70.31%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $6.00
Upside: +400.00%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $4.56
Upside: +8,671.93%